Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes o...
Guardado en:
Autores principales: | Jieun Kang, Jin Woo Song |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/98744e44e4c2472da78b957c76dcc9cc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
por: Yuzo Suzuki, et al.
Publicado: (2021) -
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
por: Ho Cheol Kim, et al.
Publicado: (2021) -
Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice
por: Jooae Choe, et al.
Publicado: (2021) -
A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis
por: Myung Jin Song, et al.
Publicado: (2021) -
Functional Wnt signaling is increased in idiopathic pulmonary fibrosis.
por: Melanie Königshoff, et al.
Publicado: (2008)